Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms

被引:2
|
作者
Keski, Hakan [1 ]
机构
[1] Kocaeli Univ, Dept Internal Med, Div Hematol, Kocaeli, Turkey
关键词
Bone marrow fibrosis; CD34; Mast cell; Myeloproliferative neoplasm; Reticulin fiber; PERIPHERAL-BLOOD; ESSENTIAL THROMBOCYTHEMIA; EUROPEAN CONSENSUS; CD34(+) CELLS; MYELOFIBROSIS; NUMBER; CLASSIFICATION; MASTOCYTOSIS; PROGNOSIS; IMPACT;
D O I
10.1016/j.bcmd.2020.102420
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We aimed to investigate the association of bone marrow mast cell numbers (MCN) and the degree of reticulin fibrosis in patients with chronic myeloproliferative neoplasms (MPN). Methods: This was a case-control study that recruited 47 patients who were diagnosed with bcr-abl negative MPN. Thirty patients with lymphoma served as controls. JAK2 mutation was studied and all subjects underwent bone marrow biopsy at the time of diagnosis. Mast and CD34 + cells were counted. Marrow reticulin fiber was graded. Results: Thirty-four patients had essential thrombocythemia (ET), 8 patients had primary myelofibrosis (PMF) and 5 patients had polycythemia vera (PV). Fourteen MPN patients had JAK2, whereas the controls had not. MCN was higher in patients than controls (p = 0.001). There was no significant difference regarding CD34. Reticulin fibrosis was present in 57.4% of MPN patients, whereas there was any in controls. PMF patients had more CD34 + cells than PV and ET. PMF patients had more reticulin fibers compared with other subgroups (p < 0.001). MCN, but not CD34 + cell counts, was significantly higher in JAK2( + ) patients than JAK2( - ) patients. Conclusion: MCN and reticulin fibrosis were significantly increased in MPN patients. JAK2 positivity had significantly increased MCN compared to patients without JAK2. JAK2 was associated with increased reticulin fibrosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution
    Schoenbeck, Kelly L.
    Cerejo, Miguel Carlos
    Cornett, Patricia A.
    Damon, Lloyd E.
    Gaensler, Karin L.
    Leavitt, Andrew D.
    Logan, Aaron C.
    Mannis, Gabriel N.
    Olin, Rebecca L.
    Salmasi, Giselle
    Sayre, Peter H.
    Shah, Neil P.
    Dhruva, Anand
    Atreya, Chloe E.
    Smith, Catherine C.
    BLOOD, 2019, 134
  • [42] Chinese Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: Immunophenotype of Myeloid Monocytes
    Liang, Fengting
    Zou, Yangyang
    Huang, Liangmei
    Pang, Dongxiao
    JinbaoPang, Xuelan
    Liang, Xuelan
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2025,
  • [43] Essential Differences in Clinical and Bone Marrow Features in BCR/ABL-Positive Thrombocythemia Compared to Thrombocythemia in the BCR/ABL-Negative Myeloproliferative Neoplasms Essential Thrombocythemia and Polycythemia Vera
    Michiels, Jan Jacques
    Pich, Achille
    De Raeve, Hendrik
    Gadisseur, Alain
    ACTA HAEMATOLOGICA, 2015, 133 (01) : 52 - 55
  • [44] Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy
    Griesshammer, Martin
    Sadjadian, Parvis
    Wille, Kai
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (09) : 697 - 706
  • [45] Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms
    Liang, Fengting
    Liang, Xuelan
    Pan, Lingang
    Jin, Qianni
    Deng, Ju
    Hong, Minglin
    Wei, Wei
    Hao, Zhuanghui
    Ren, Huanying
    Wang, Hongwei
    Chen, Xiuhua
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [46] DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment
    Xiong, Hao
    Liao, Minjing
    Zhang, Huitao
    Li, Yanhong
    Bai, Jun
    Zhang, Jinping
    Li, Lijuan
    Zhang, Liansheng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
    Mughal, Tariq I.
    Gotlib, Jason
    Mesa, Ruben
    Koschmieder, Steffen
    Khoury, H. Jean
    Cortes, Jorge E.
    Barbui, Tiziano
    Hehlmann, Rudiger
    Mauro, Michael
    Saussele, Susanne
    Radich, Jerald P.
    Van Etten, Richard A.
    Saglio, Giuseppe
    Verstovek, Srdnan
    Gale, Robert Peter
    Abdel-Wahab, Omar
    LEUKEMIA RESEARCH, 2018, 67 : 67 - 74
  • [48] Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing
    Kirschner, Martin M.
    Schemionek, Mirle
    Schubert, Claudia
    Chatain, Nicolas
    Sontag, Stephanie
    Isfort, Susanne
    Ortiz-Bruechle, Nadina
    Bennemann, Karla
    Zerres, Klaus
    Zenke, Martin
    Bruemmendorf, Tim H.
    Koschmieder, Steffen
    BLOOD, 2013, 122 (21)
  • [49] Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms
    Cvetkovic, Mirjana
    Arsenovic, Isidora
    Smiljanic, Mihailo
    Sobas, Marta
    Bogdanovic, Andrija
    Lekovic, Danijela
    ANNALS OF HEMATOLOGY, 2024, 103 (11) : 4545 - 4556
  • [50] Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
    Elizabeth M. Kander
    Sania Raza
    Zheng Zhou
    Juehua Gao
    Anaadriana Zakarija
    Brandon J. McMahon
    Brady L. Stein
    International Journal of Hematology, 2015, 102 : 587 - 593